Investor Presentaiton

Investor presentation Full year 2018 TresibaⓇ has since launch gained around 15% market share in the USA Slide 9 Weekly TRX volume market shares¹ in the USA - glargine U100 Basal volume TRX MS1 70% 60% 50% 40% 30% 20% 10% NN total basal² TresibaⓇ LevemirⓇ glargine U300 biosimilar glargine U100 37.8% 36.3% 21.3% 14.6% 11.1% 8.8% TresibaⓇ in the USA Novo Nordisk basal insulin volume market share is now 36.3%, which is a 9%-points increase since the launch of TresibaⓇ in 2016 • TresibaⓇ volume market share is at 14.6% • TresibaⓇ formulary access is above 80% for Commercial and Medicare Part D combined In April 2018, promotional activities were initiated for the updated TresibaⓇ label³ 0% Apr 2016 Dec 2018 Note: The graph does not show NPH, which accounts for the residual market share Source: IQVIA weekly Xponent Plantrak (*excludes Medicaid), 28 Dec 2018 TRX volume: Insulin volume in mega units (MU) associated with total number of prescriptions; VANTAGE FingerTip Formulary bridge, Dec 2018 MS: Market share 1 Excluding Medicaid, Medicaid represents ~12% of retail basal market volume, 2 Includes XultophyⓇ 3 TresibaⓇ label was updated in March 2018 to include a 40% reduction of severe hypoglycaemic events compared to insulin glargine U100 novo nordisk

View entire presentation